CA19-9 is a tumor marker elevated in the blood of patients with carcinoma of the gastro-intestinal tract. It is primarily used to distinguished pancreatic cancer from pancreatitis. CA19-9 is not sufficiently specific for use as a cancer screening test. The specificity for pancreatic cancer increases with increasing levels, high levels showing a specificity of >97% for tumour presence.SCIPAC CA19-9 antibodies show excellent performance compared with antibodies available in commercial immunoassays currently on the market.
| Abbreviation | CA19-9 mAb |
| Variant Name | Product Code | Purity | |
|---|---|---|---|
+ |
CA19-9 mAb clone G5H5 | BM238-G5H5 | |
+ |
CA19-9 mAb clone G6C8 | BM238-G6C8 | |
+ |
CA19-9 mAb clone H4H1 | BM238-H4H1 | |
+ |
CA19-9 mAb clone H7D1 | BM238-H7D1 | |
+ |
CA19-9 mAb clone P6A7 | BM238-P6A7 | |